Expanded Access for Dasatinib

Brief Summary

This is an expanded access designed to provide access to dasatinib for eligible participants.

Status

No longer available

EA Type

Individual Patients

Interventions

Drug: Dasatinib

Countries

Australia

Belgium

Brazil

Canada

France

Italy

Latvia

Liberia

Mexico

Spain

United States

Locations

Local Institution
New York, New York, 10065

Available

Investigator: Site 0024

Local Institution
Charlottesville, Virginia, 22908

Available

Investigator: Site 003

Investigators

Bristol-Myers Squibb, Study Director
Bristol-Myers Squibb, Korea

NCT Number

NCT00454753

MeSH Terms

Dasatinib

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA